±¹Á¦¾Ï´ëÇпø´ëÇб³ Á¤À¯¼® ±³¼ö, ¾ÏÇÐȸ Çмú»ó ¼ö»ó

´º½ºÀÏÀÚ: 2015³â07¿ù01ÀÏ 17½Ã51ºÐ

»çÁø)Á¤À¯¼® ±³¼ö(ÁÂ) ÀÌ»óÁø ±³¼ö(¿ì)
[º¸°ÇŸÀÓÁî] ±¹¸³¾Ï¼¾ÅÍ ±¹Á¦¾Ï´ëÇпø´ëÇб³ ¾Ï°ü¸®Á¤Ã¥Çаú Á¤À¯¼® ±³¼ö ¿¬±¸ÆÀ(½Ã½ºÅÛÁ¾¾ç»ý¹°Çаú ÀÌ»óÁø ±³¼ö)ÀÌ  Áö³­´Þ 19ÀÏ ¼­¿ï ¼Ò°øµ¿ ·Ôµ¥È£ÅÚ¿¡¼­ °³ÃÖµÈ ‘Á¦41Â÷ ´ëÇѾÏÇÐȸ Çмú´ëȸ’¿¡¼­ ³ë¹ÙƼ½º Merit Award Çмú ÃÖ¿ì¼ö»óÀ» ¼ö»óÇß´Ù. 

¹ßÇ¥µÈ ³í¹®Àº µÎ°æºÎ¾Ï µ¿¹°¸ðµ¨¿¡¼­ À¯ÀüÀÚÄ¡·á¿Í Àú¿ë·® Ç×¾ÏÁ¦ÀÇ º´ÇÕ¿ä¹ýÀÇ È¿°ú ¹× ±âÀüÀ» Æò°¡ÇÏ´Â ¿¬±¸ÀÎ 'Low-dose cisplatin converts the tumor microenvironment into a permissive state for HSVtk-induced antitumor immunity in HPV16-related tonsillar carcinoma'´Ù. 

 


ÀÌ ´º½ºÅ¬¸®ÇÎÀº BKT´º½º{www.bktimes.net}¿¡¼­ ¹ßÃéµÈ ³»¿ëÀÔ´Ï´Ù.